GlassScriptPhysician profile
Maria B Weimer
NPI 1659394518
$5,771.52
in general payments reported to CMS, 2019-2025
38 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $458 · 2021: $830 · 2022: $926 · 2023: $1,145 · 2024: $879 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $855.21 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Eisai INC. | $435.05 | 2019-2023 | |
| Sk Life Science, INC. | $410.92 | 2021-2024 | Xcopri |
| Neurelis, INC. | $393.96 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $391.16 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $367.19 | 2019-2022 | |
| Ptc Therapeutics, INC. | $343.49 | 2019-2025 | Emflaza |
| Sarepta Therapeutics, INC. | $299.82 | 2019-2025 | Elevidys, Exondys 51 |
| Biogen, INC. | $279.54 | 2019-2025 | Spinraza, Skyclarys, Skyclarys |
| Sunovion Pharmaceuticals INC. | $204.42 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $188.72 | 2019-2025 | Brineura |
| Genentech, INC. | $154.61 | 2022 | |
| Immedica Pharma US, INC. | $117.27 | 2022-2025 | Ztalmy |
| Argenx US, INC. | $115.42 | 2024 | Vyvgart |
| Genentech USA, INC. | $103.63 | 2022-2025 | Evrysdi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $95.24 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $93.36 | 2024-2025 | |
| Ns Pharma, INC. | $92.65 | 2021-2024 | Viltepso |
| Greenwich Biosciences, INC. | $89.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $85.65 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $82.01 | 2022-2025 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $72.51 | 2019-2022 | |
| Zevra Therapeutics INC | $72.46 | 2025 | Olpruva |
| Itf Therapeutics LLC | $57.47 | 2024-2025 | |
| Biocodex, INC. | $55.34 | 2024 | |
| Aucta Pharmaceuticals, INC. | $49.18 | 2025 | Motpoly Xr |
| Zogenix INC. | $45.93 | 2021 | |
| Csl Behring | $32.56 | 2023 | Hizentra |
| Mallinckrodt Enterprises LLC | $28.19 | 2019 | |
| Acadia Pharmaceuticals INC | $22.80 | 2023 | Daybue |
| Abbvie INC. | $19.86 | 2022 | |
| Mirum Pharmaceuticals, INC. | $19.00 | 2024 | Cholbam |
| Strongbridge US INC. | $18.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.45 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.75 | 2022 | |
| Metacel Pharmaceuticals LLC | $16.91 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.72 | 2019 | |
| Emd Serono, INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Weimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.